BG Medicine, Inc. Prices $12.0 Million Public Offering of Common Stock
WALTHAM, Mass., Jan. 25, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a diagnostics company focused on the development and
commercialization of novel cardiovascular tests, today announced the sale of
6,000,000 shares of its common stock in an underwritten public offering at a
price to the public of $2.00 per share. The net offering proceeds to BG
Medicine from the sale of the shares are expected to be approximately $11.1
million, after deducting underwriting discounts and commissions and other
estimated offering expenses, but excluding any exercise of the underwriter's
BG Medicine anticipates using the net proceeds from this offering for its
operations, including, advancing the commercialization of its cardiovascular
diagnostic tests in the United States and Europe; and other general corporate
purposes, including capital expenditures, licensing of intellectual property,
repayment of indebtedness and working capital.
The offering is expected to close on or about January 30, 2013, subject to
customary closing conditions. In addition, BG Medicine has granted the
underwriters a 30-day option to purchase up to an additional 900,000 shares of
common stock on the same terms and conditions, solely to cover
over-allotments, if any.
Lazard Capital Markets LLC is acting as the sole book-running manager for the
The shares described above will be issued pursuant to a prospectus supplement
filed as part of a shelf registration statement on Form S-3 previously filed
with and declared effective by the Securities and Exchange Commission ("SEC").
The offering may be made only by means of a prospectus supplement and the
accompanying prospectus, copies of which may be obtained by sending a request
to: Lazard Capital Markets LLC, 30 Rockefeller Plaza, New York, NY 10020 or
via telephone at (800) 542-0970. BG Medicine intends to file a final
prospectus supplement relating to the offering with the SEC, which will be
available along with the accompanying prospectus filed with the SEC in
connection with the shelf registration, on the SEC's website at www.sec.gov.
This press release does not constitute an offer to sell or a solicitation of
an offer to buy any securities of BG Medicine, nor shall there be any sale of
securities in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. This press release is being
issued pursuant to and in accordance with Rule 134 under the Securities Act of
1933, as amended.
About BG Medicine
BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company has two products: the BGM Galectin-3^® test for
use in patients with chronic heart failure is available in the United States
and Europe; and the CardioSCORE™ test for the risk prediction of major
cardiovascular events will be launched in Europe in the first half of 2013.
For additional information about BG Medicine, heart failure and galectin-3
testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at
Cautionary Statement Regarding Forward-Looking Statements
This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect BG Medicine's future operating
results and financial position. Such statements, including, but not limited
to, those regarding statements about BG Medicine's expectations regarding its
fundraising efforts, including the closing of the public offering, the
anticipated use of proceeds from the offering and the underwriter's exercise
of its over-allotment option, involve known and unknown risks that relate to
BG Medicine's future events or future financial performance and the actual
results could differ materially from those discussed in this communication.
Risks and uncertainties that may cause BG Medicine's actual results to differ
materially from those discussed in this communication can be found in the
"Risk Factors" section of BG Medicine's preliminary prospectus supplement and
Current Report on Form 8-K both filed on January 24, 2013, Form 10-K, Forms
10-Q and its other filings with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof, and BG Medicine assumes no
responsibility to update or revise any forward-looking statements contained in
this communication to reflect events, trends or circumstances after the date
of this communication.
CONTACT: Chuck Abdalian
EVP & Chief Financial Officer
BG Medicine Inc. logo
Press spacebar to pause and continue. Press esc to stop.